G-CSF or GM-CSF application may lead to different outcomes in different stages of severe sepsis and is more applicable in patients with severe immunosuppression, making individualized and precise therapy guided by biomarkers based on immune status extremely important. The gene discussed is CSF3; the disease is Sepsis.